Search

Your search keyword '"Sanuki N"' showing total 42 results

Search Constraints

Start Over You searched for: Author "Sanuki N" Remove constraint Author: "Sanuki N" Topic radiosurgery Remove constraint Topic: radiosurgery
42 results on '"Sanuki N"'

Search Results

1. Final Results of a Multicenter Prospective Study of Stereotactic Body Radiation Therapy for Previously Untreated Solitary Primary Hepatocellular Carcinoma (The STRSPH Study).

2. Local control correlates with overall survival in radiotherapy for early-stage non-small cell lung cancer: A systematic review.

Catalog

Books, media, physical & digital resources

3. Role of stereotactic body radiotherapy in multidisciplinary management of liver metastases in patients with colorectal cancer.

4. Applying Artificial Neural Networks to Develop a Decision Support Tool for Tis-4N0M0 Non-Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy.

5. Stereotactic Body Radiation Therapy With a High Maximum Dose Improves Local Control, Cancer-Specific Death, and Overall Survival in Peripheral Early-Stage Non-Small Cell Lung Cancer.

6. Stereotactic body radiotherapy for primary non-small cell lung cancer patients with clinical T3-4N0M0 (UICC 8th edition): outcomes and patterns of failure.

7. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis.

8. Stereotactic body radiotherapy for patients with non-small-cell lung cancer using RapidArc delivery and a steep dose gradient: prescription of 60% isodose line of maximum dose fitting to the planning target volume.

10. Stereotactic body radiotherapy for lung cancer patients with idiopathic interstitial pneumonias.

11. Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.

12. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation.

13. Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83-100 Gy in five fractions.

14. Stereotactic body radiotherapy for T3 and T4N0M0 non-small cell lung cancer.

15. Stereotactic body radiotherapy for chronic obstructive pulmonary disease patients undergoing or eligible for long-term domiciliary oxygen therapy.

17. Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume.

18. Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors.

19. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer.

20. Role of stereotactic body radiation therapy for hepatocellular carcinoma.

21. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.

22. Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA.

23. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma.

24. Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy.

26. Stereotactic ablative body radiation therapy with dynamic conformal multiple arc therapy for liver tumors: optimal isodose line fitting to the planning target volume.

27. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis.

28. Salvage stereotactic ablative irradiation for isolated postsurgical local recurrence of lung cancer.

29. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.

30. Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma - benchmark for a prospective multi-institutional study.

31. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system.

32. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.

33. Reassessment of declines in pulmonary function ≥1 year after stereotactic body radiotherapy.

34. Dose volume histogram analysis of focal liver reaction in follow-up multiphasic CT following stereotactic body radiotherapy for small hepatocellular carcinoma.

35. Stereotactic body radiotherapy (SBRT) for solitary pulmonary nodules clinically diagnosed as lung cancer with no pathological confirmation: comparison with non-small-cell lung cancer.

36. Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours.

37. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT).

38. Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors.

39. Dose distribution analysis in stereotactic body radiotherapy using dynamic conformal multiple arc therapy.

40. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.

41. [Discrepancy between the intended isocenter and that from orthogonal linacgrams in the treatment of CT-guided stereotactic body radiotherapy(SBRT)].

42. Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing.